
    
      Subjects who signed the informed consent were assigned to three cohorts according to the
      actual treatment status. Cohort 1 enrolled subjects receiving PD-L1/CTLA4 BsAb 5mg/kg iv Q2W
      for 2nd treatment; cohort 2 enrolled subjects receiving PD-L1/CTLA4 BsAb in combination with
      gemcitabine/albumin- paclitaxel as 1st treatment for 4-6 cycles with PD-L1/CTLA4 BsAb
      monotherapy maintainence; cohort 3 enrolled subjects received systemic chemotherapy,
      receiving PD-L1/CTLA4 BsAb combined with oxaliplatin / irinotecan / leucovorin / fluorouracil
      (FOLFIRINOX) as 1st treatment for 4-6 cycles withPD-L1/CTLA4 BsAb monotherapy maintainence;
      until disease progression according to RECIST 1.1, intolerable toxicity, withdrawal, death,
      2-yr treatment,who comes first.
    
  